Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).

Related Keywords

United States ,American , ,American Academy Of Dermatology ,American Journal ,American Academy ,Jeff Stark ,